Lamidetan solid preparation and preparation method thereof
By using anti-adsorbents such as lactose and sodium dodecyl sulfate in ramiditan preparations, combined with other fill and disintegrants, the adsorption and crystalline stability of the preparations are solved, and rapid disintegration and stability are achieved The bioavailability simplifies the preparation process and is suitable for industrial production.
Patent Information
- Application Number
- CN202310648538.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-06-02
- Publication Date
- 2024-12-03
AI Technical Summary
Lamidetan preparations have strong adsorption and bonding problems, resulting in unstable bioavailability. The existing technology has failed to effectively solve the problems of crystal form stability and disintegration time limit.
Using lactose and sodium dodecyl sulfate as anti-adsorbents, combined with microcrystalline cellulose, croscarmellose sodium and magnesium stearate, solid preparation is prepared by direct powder pressing or dry granulation, and control Raw material ratio is used to achieve anti-adsorption and disintegration effects, and avoid high-shear wet granulation.
The rapid disintegration and stable crystal form of the solid preparation of ramidatan is achieved, ensuring the bioavailability and therapeutic effect of the drug, simplifying the preparation process, and suitable for industrial production.
Smart Images

Figure BDA0004264204170000011 
Figure BDA0004264204170000021 
Figure BDA0004264204170000031
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of medical technology, and in particular relates to a lamiditan solid preparation and a preparation method thereof. Background Art
[0002] Lasmiditan was launched in the United States in October 2019 under the trade name Reyvow. It is the first 5-HT 1F Receptor agonist. This drug targets and binds with high affinity to 5-HT in the trigeminal nerve pathway 1F It can penetrate the central nervous system to relieve migraine symptoms without vasoconstriction. Indications: It is suitable for the acute treatment of adult migraine patients with or without aura symptoms.
[0003] The chemical name is 2,4,6-trifluoro-N-[6-[(1-methyl-4-piperidinyl)carbonyl]-2-pyridinyl]benzamide, molecular formula: C 19 H 18 F3N3O2, molecular weight: 377.36, structural formula is as follows:
[0004]
[0005] Patients with migraine who took lamiditan hemisuccinate tablets orally were rapidly absorbed and reached a peak plasma drug concentration (C max The median time (t max ) is 1.8h. There is no difference in the absorption and pharmacokinetic parameters of lamivudine in patients with migraine during the attack and the interval between attacks. When taking the drug with a high-fat meal, the C max and AUC mean increased by 22% and 19%, respectively. max Delay of 1h.
[0006] Patent CN110291079A discloses a composition and method related to a pyridylpiperidine 5-HT1F agonist, which is a novel pseudopolymorph of the hemisuccinate of 2,4,6-trifluoro-N-[6-(1-methyl-piperidine-4-carbonyl)-pyridin-2-yl]-benzamide that can be used, for example, in a pharmaceutical composition for treating and preventing migraine. The pharmaceutical composition comprises a mixture of polymorphs of Compound I, the mixture being selected from a mixture of crystalline forms A and D, a mixture of crystalline forms A and E, a mixture of crystalline forms D and E, and a mixture of crystalline forms A, D, and E. No data on the stability of the crystalline forms in the stability study is provided.
[0007] Since the crystal form of lamiditan hemisuccinate A is affected by water, crystal transformation will occur in different proportions of water. The bioavailability of the drug may be different due to different crystal forms, which in turn affects the efficacy of the drug.
[0008] Patent WO2022 / 079591A1 discloses a pharmaceutical composition and preparation method of lamiditan. The pharmaceutical composition is prepared by a dry manufacturing process, but the patent does not involve the disintegration time and crystal stability of the composition.
[0009] In addition, through many tests and investigations, it was found that lamiditan has high viscosity and strong adsorption, and the content was obviously low during the content detection process; the EMA review report of lamiditan tablets (Reyvow) also mentioned that lamiditan has adhesion and adsorption problems, and high shear wet granulation is needed to solve the adhesion problem.
[0010] In view of the above problems existing in the lamiditan preparations, it is necessary to research and develop a lamiditan solid preparation with a composition content that meets the requirements, a stable crystal form, and a rapid onset of action. Summary of the invention
[0011] In view of the shortcomings of the prior art, the researchers of the present invention have discovered, through a large number of experimental investigations, a solid preparation of lamiditan that can inhibit adsorption and maintain crystal stability, and provided a method for preparing the solid preparation. Under the technical scheme of the present invention, the solid preparation can disintegrate rapidly and take effect quickly.
[0012] The specific technical solutions of the present invention are as follows:
[0013] In one aspect, the present invention provides a lamiditan solid preparation, which is prepared from the following raw materials: lamiditan, an anti-adsorbent, a filler, a disintegrant, and a lubricant.
[0014] Preferably, the lamiditan is lamiditan hemisuccinate.
[0015] Preferably, the lamiditan is lamiditan hemisuccinate crystal form A.
[0016] Preferably, the anti-adsorption agents are lactose and sodium lauryl sulfate.
[0017] Through a large number of experiments, the inventor unexpectedly discovered that the combined use of lactose and sodium dodecyl sulfate can play a good role in anti-adsorption and adhesion; when the weight ratio of lactose and sodium dodecyl sulfate is controlled to be 1-40:1, the anti-adsorption and adhesion effects are best.
[0018] Further preferably, the weight ratio of lactose to sodium dodecyl sulfate in the anti-adsorption agent is 15 to 30:1.
[0019] Preferably, the filler is selected from one or more of microcrystalline cellulose, pregelatinized starch, starch, calcium hydrogen phosphate, and mannitol; preferably microcrystalline cellulose and pregelatinized starch.
[0020] Preferably, the disintegrant is one of cross-linked sodium carboxymethyl starch and cross-linked sodium carboxymethyl cellulose; preferably cross-linked sodium carboxymethyl cellulose.
[0021] Preferably, the lubricant is one or more of magnesium stearate, calcium stearate, talc, sodium stearate fumarate; preferably magnesium stearate.
[0022] Preferably, the solid preparation may be a coating agent or a plain tablet.
[0023] In some embodiments, the solid dosage form further comprises a coating agent.
[0024] Preferably, the coating agent is composed of the following raw materials: polyvinyl alcohol, titanium dioxide, triglyceride and red iron oxide; preferably, the coating agent is a gastric-soluble film coating premix, which can be obtained through commercial channels.
[0025] Preferably, the solid preparation is prepared from the following raw materials in parts by weight:
[0026]
[0027]
[0028] In one embodiment, the solid preparation is prepared from the following raw materials in parts by weight:
[0029]
[0030] In a preferred embodiment, the solid preparation is prepared from the following raw materials in parts by weight:
[0031]
[0032] On the other hand, the present invention also provides a method for preparing the above solid preparation, comprising a powder direct compression method and a dry granulation method.
[0033] Preferably, the powder direct compression method comprises the following steps: uniformly mixing lamiditan with an anti-adsorbent, a filler, a disintegrant and a lubricant, and tableting with or without coating.
[0034] Preferably, the dry granulation comprises the following steps: mixing lamiditan with one or more auxiliary materials selected from anti-adsorbents, fillers, disintegrants and lubricants to form a lamiditan complex, and dry granulating the mixture; adding the remaining auxiliary materials and mixing evenly; tabletting; and coating or not coating the mixture.
[0035] In one embodiment, the dry granulation steps are as follows: mixing lamiditan with an anti-adsorbent to form a lamiditan complex, and dry granulating; then adding a filler and a disintegrant and mixing evenly; then adding a lubricant and mixing evenly; tableting; and coating or not coating is optional.
[0036] Beneficial effects of the present invention:
[0037] The present invention provides a lamiditan solid preparation. The inventor unexpectedly found a method for solving the problem of raw material adhesion without using high shear wet granulation during the research process. At the same time, the solid preparation of the present invention can keep the raw material drug in a single crystal form, and the crystal form is stable during the stability investigation. Compared with the prior art, the solid preparation of the present invention has a stable content, a stable crystal form during production and storage, and rapid disintegration, and a simple preparation process, which is easy to scale up and suitable for industrial production. BRIEF DESCRIPTION OF THE DRAWINGS
[0038] Figure 1 .X-ray powder diffraction pattern of Example 1 after 6 months of accelerated stability study.
[0039] Figure 2 .X-ray powder diffraction pattern of Comparative Example 1 after 6 months of accelerated stability study. DETAILED DESCRIPTION
[0040] The beneficial effects of the present invention are further described below by way of examples. It should be understood that the following examples are only for illustrative purposes and are not intended to limit the scope of protection of the present invention. At the same time, obvious changes and modifications made by ordinary technicians in the field according to the present invention are also included in the scope of protection of the present invention.
[0041] The active ingredients in each example are all in crystal form A, and the weight portions of the active ingredients in the example preparations are all calculated as free bases. The film coating premix can be homemade or obtained from commercial sources.
[0042] Example 1
[0043] prescription:
[0044]
[0045] Preparation process:
[0046] (1) Mix the prescribed amount of lamiditan hemisuccinate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, lactose, cross-linked sodium carboxymethyl cellulose, and magnesium stearate uniformly;
[0047] (2) Tablets, gastric soluble film coating premix.
[0048] Example 2
[0049] prescription:
[0050]
[0051]
[0052] Preparation process:
[0053] (1) Mix the prescribed amount of lamiditan hemisuccinate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, lactose, cross-linked sodium carboxymethyl cellulose, and magnesium stearate uniformly;
[0054] (2) Tablets, gastric soluble film coating premix.
[0055] Example 3
[0056] prescription:
[0057]
[0058] Preparation process:
[0059] (1) Mix the prescribed amount of lamiditan hemisuccinate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, lactose, cross-linked sodium carboxymethyl cellulose, and magnesium stearate uniformly;
[0060] (2) Tablets, gastric soluble film coating premix.
[0061] Example 4
[0062] prescription:
[0063]
[0064]
[0065] Preparation process:
[0066] (1) Mix the prescribed amount of lamiditan hemisuccinate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, lactose, cross-linked sodium carboxymethyl cellulose, and magnesium stearate uniformly;
[0067] (2) Tablets, gastric soluble film coating premix.
[0068] Example 5
[0069] prescription:
[0070]
[0071] Preparation process:
[0072] (1) Mix the prescribed amount of lamiditan hemisuccinate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, lactose, cross-linked sodium carboxymethyl cellulose, and magnesium stearate uniformly;
[0073] (2) Tablets, gastric soluble film coating premix.
[0074] Example 6
[0075] prescription:
[0076]
[0077]
[0078] Preparation process:
[0079] (1) mixing the prescribed amount of lamiditan hemisuccinate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, lactose, and cross-linked sodium carboxymethyl cellulose uniformly, and dry granulating;
[0080] (2) Add magnesium stearate, compress the tablets, and coat the premix with a gastric soluble film coating.
[0081] Example 7
[0082]
[0083] Preparation process:
[0084] (1) mixing lamiditan hemisuccinate, lactose, and sodium lauryl sulfate uniformly, and dry granulating;
[0085] (2) Add microcrystalline cellulose, pregelatinized starch, cross-linked sodium carboxymethyl cellulose, and magnesium stearate, mix well, compress into tablets, and coat with a gastric soluble film coating premix.
[0086] Example 8
[0087]
[0088] Preparation process:
[0089] (1) mixing lamiditan hemisuccinate, lactose, and sodium lauryl sulfate uniformly, and dry granulating;
[0090] (2) Add microcrystalline cellulose, pregelatinized starch, cross-linked sodium carboxymethyl cellulose, and magnesium stearate, mix well, compress into tablets, and coat with a gastric soluble film coating premix.
[0091] Example 9
[0092]
[0093] Preparation process:
[0094] (1) mixing lamiditan hemisuccinate, lactose, and sodium lauryl sulfate uniformly, and dry granulating;
[0095] (2) Add microcrystalline cellulose, pregelatinized starch, cross-linked sodium carboxymethyl cellulose, and magnesium stearate, mix well, compress into tablets, and coat with a gastric soluble film coating premix.
[0096] Example 10
[0097] prescription:
[0098]
[0099] Preparation process:
[0100] (1) Mix the prescribed amount of lamiditan hemisuccinate, microcrystalline cellulose, pregelatinized starch, lactose, cross-linked sodium carboxymethyl cellulose, and magnesium stearate uniformly;
[0101] (2) Tableting.
[0102] Comparative Example 1
[0103] prescription:
[0104]
[0105]
[0106] Preparation process:
[0107] (1) Mix the prescribed amount of lamiditan hemisuccinate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, lactose, cross-linked sodium carboxymethyl cellulose, and magnesium stearate uniformly;
[0108] (2) Tablets, gastric soluble film coating premix.
[0109] Comparative Example 2
[0110] prescription:
[0111]
[0112] Preparation process:
[0113] (1) High shear wet granulation: Sodium lauryl sulfate is passed through a safety sieve and added to purified water to form a granulation liquid. Lamiditan hemisuccinate is mixed with microcrystalline cellulose, pregelatinized starch, and cross-linked sodium carboxymethyl cellulose in a granulator. The granulation liquid is added, mixed, granulated, and dried.
[0114] (2) Add extragranular cross-linked sodium carboxymethyl cellulose and magnesium stearate, mix, compress, and apply a gastric soluble film coating premix.
[0115] Comparative Example 3
[0116] prescription:
[0117]
[0118]
[0119] Preparation process:
[0120] (1) uniformly mixing the prescribed amount of lamiditan hemisuccinate, microcrystalline cellulose, pregelatinized starch, sodium lauryl sulfate, cross-linked sodium carboxymethyl cellulose, and magnesium stearate;
[0121] (2) Tablets, gastric soluble film coating premix.
[0122] Comparative Example 4
[0123] prescription:
[0124]
[0125] Preparation process:
[0126] (1) mixing the prescribed amount of lamiditan hemisuccinate, microcrystalline cellulose, sodium lauryl sulfate, pregelatinized starch, cross-linked sodium carboxymethyl cellulose, and magnesium stearate uniformly;
[0127] (2) Tablets, gastric soluble film coating premix.
[0128] Comparative Example 5
[0129] prescription:
[0130]
[0131]
[0132] Preparation process:
[0133] (1) Mix lamiditan hemisuccinate, microcrystalline cellulose, sodium lauryl sulfate, and low-substituted hydroxypropyl cellulose evenly.
[0134] (2) Add magnesium stearate and mix well, compress into tablets, and coat with Opadry.
[0135] Comparative Example 6
[0136] prescription:
[0137]
[0138] Preparation process:
[0139] (1) Mix lamiditan hemisuccinate, microcrystalline cellulose, anhydrous lactose, sodium lauryl sulfate, and low-substituted hydroxypropyl cellulose.
[0140] (2) Add magnesium stearate and mix well, compress into tablets, and coat with Opadry.
[0141] Verification Example
[0142] 1. Determination of disintegration time
[0143] According to the original EU instructions, due to the fast dissolution rate of the drug, the identification ability of the dissolution method is insufficient, so the disintegration time is used instead of dissolution to examine the differences between the preparations. According to the General Rules 0921 of the Fourth Part of the 2020 Edition of the Chinese Pharmacopoeia, the disintegration time of Examples 1-10 and Comparative Examples 1-6 was measured, and the specific results are shown in Table 1.
[0144] Table 1 Disintegration time measurement results of Examples 1-10 and Comparative Examples 1-6
[0145]
[0146]
[0147] 2. Stability test
[0148] According to the General Rules 9001 and 9015 of the Fourth Volume of the Chinese Pharmacopoeia 2020 Edition, the samples prepared in Examples 1-10 and Comparative Examples 1-6 were stored under accelerated test conditions for 6 months, and the content and related substances were determined at 0, 3, and 6 months, respectively. The crystal stability was determined by X-ray powder diffraction. The specific results are shown in Table 2.
[0149] Table 2 Stability test results of Examples 1-10 and Comparative Examples 1-6
[0150]
[0151]
[0152] The X-ray powder diffraction pattern of Form A of the sample in Example 1 after 6 months of accelerated stability testing is shown in the attached figure. Figure 1 As shown, the crystal form A at the detection points corresponding to Table 2 in the remaining embodiments has the same Figure 1 The X-ray powder diffraction pattern is basically the same; after the sample in Comparative Example 1 was investigated under accelerated stability conditions for 6 months, the X-ray powder diffraction pattern of the mixed crystal is as shown in the attached Figure 2 As shown, the mixed crystals at the detection points in Table 2 in the other embodiments have the same Figure 1 Similar or more mixed crystal X-ray powder diffraction pattern.
Claims
1. A lamiditan solid preparation, characterized in that: The solid preparation is prepared from the following raw materials: lamiditan, an anti-adsorption agent, a filler, a disintegrant and a lubricant.
2. The solid preparation according to claim 1, characterized in that The lamiditan is lamiditan hemisuccinate, more preferably lamiditan hemisuccinate crystal form A.
3. The solid preparation according to any one of claims 1 to 2, characterized in that: The anti-adsorption agents are lactose and sodium lauryl sulfate.
4. The solid preparation according to claim 3, characterized in that The weight ratio of lactose to sodium lauryl sulfate is 1-40:1, preferably 15-30:
1.
5. The solid preparation according to claim 1, characterized in that The filler is selected from one or more of microcrystalline cellulose, pregelatinized starch, starch, calcium hydrogen phosphate, and mannitol; preferably microcrystalline cellulose and pregelatinized starch.
6. The solid preparation according to claim 1, characterized in that The disintegrant is one of cross-linked sodium carboxymethyl starch and cross-linked sodium carboxymethyl cellulose; preferably cross-linked sodium carboxymethyl cellulose.
7. The solid preparation according to claim 1, characterized in that The lubricant is one or more of magnesium stearate, calcium stearate, talc, and sodium stearyl fumarate; preferably magnesium stearate.
8. The solid preparation according to any one of claims 1 to 2, characterized in that: Made from the following raw materials in parts by weight:
9. A method for preparing the solid preparation according to any one of claims 1 to 2, characterized in that: Including powder direct compression and dry granulation.
10. The preparation method according to claim 9, characterized in that: The powder direct compression method comprises the following steps: uniformly mixing lamiditan with an anti-adsorbent, a filler, a disintegrant, and a lubricant, and tableting, and the tablets may be coated or uncoated; the dry granulation method comprises the following steps: mixing lamiditan with one or more auxiliary materials selected from the group consisting of an anti-adsorbent, a filler, a disintegrant, and a lubricant to form a lamiditan complex, dry granulating, and then adding the remaining auxiliary materials and mixing uniformly, and tableting, and the tablets may be coated or uncoated.
